FEELM
21.11.2022 13:48:38 CET | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won Best Innovation in the Vaping Industry and Sustainable Vaping Award at the UKVIA Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005487/en/
FEELM won the UKVIA Best Innovation Award. (Photo: Business Wire)
UKVIA is one of the world's most influential trade associations for the vaping sector. It is also one of the most accredited industrial association in Europe. This is the first time they held an award competition ever since their establishment in 2016. The competition is consisted of three sessions: online application, audiences review, and experts scoring. FEELM Max won the victory after rounds of assessments of more than 300 audiences and 10 experts.
The Best Innovation in the Vaping Industry
The Best Innovation in the Vaping Industry recognized the significant contribution FEELM has made to vaping innovation, particularly its world's first ceramic coil disposable pod solution FEELM Max.
FEELM Max has made a number of breakthrough innovations, including more puffs with the same e-liquid volume versus other coil technologies. Despite heating the same e-liquid volume as other conventional devices, puff numbers increase by more than 25%. FEELM Max achieves a flavour consistency of over 95% as well as a smoother vapour – and there is no dry burning – thanks to Constant Output Control and our Patented Flavour-Lock Technologies. Not only is FEELM Max enhancing the vaping experience, but it is also outperforming other disposables on harm reduction by almost 50%.
To stand still on the path of innovation, FEELM has established China’s first PMTA-standard testing lab besides the now-existing 14 labs globally, to empower our clients facing with the stringent regulations on the industry. This is to prove our determination to drive innovation with technology, and keep providing products with enhanced quality to consumers.
The Sustainable Vaping Award
The Sustainable Vaping Award was given in recognition of FEELM excelling in three key areas: creating sustainable advanced technologies and products; using responsible marketing; and embracing a greener future.
FEELM is credited with building the world's first environmentally friendly disposable electronic atomization device in 2019. In 2022, the world's first ceramic coil disposable pod "FEELM Max" was created and the "FEELM GREEN" series was launched based on it. This series is FEELM Max's main environmental protection solutions, its latest "product is packaging" series has been presented at the major European electronic atomization exhibition, aroused the industry's high attention. In addition, FEELM also created an environmentally friendly zero nicotine e-atomization device this year.
It was also acknowledged that its brand website and social media platforms go to great lengths to restrict those who are under the legal age of vaping to prevent them from accessing any information about electronic atomization products; and that FEELM conducts regular satisfaction surveys on behalf of clients so data can be used to improve customer experience.
FEELM has announced its launching of the Carbon Disclosure Project (CDP), committing to achieve carbon neutrality by 2050, and its automated factory has adopted an energy management system with the purpose of decreasing carbon emissions whilst increasing energy consumption efficiency
The Award is also recognition of FEELM’s cut in carbon emissions of over 500 tons in the last six months, and its aim to lower greenhouse gas emissions and achieve Scope 1 and Scope 2 carbon neutrality by 2050. The company intends to achieve this by improving energy efficiency and increasing the use of renewable energy sources to 30% of total consumption by 2030 and has accordingly introduced a professional carbon neutral energy screening team and internal resources to monitor carbon consumption improvement. It has also partnered with a third-party cleaning company to collect non-hazardous waste for recycling, which in 2020 helped clients reduce single-use plastics by 100 tons – equivalent to 4 million plastic bottles, while in 2021 it reduced its water consumption by 9.4% year-on-year.
Echo liu, FEELM Europe Division Director said:
“We are delighted to have won both awards and honoured by the recognition the UKVIA have given us.”
“A number of leading vaping brands are driven by FEELM Technology, and our vaping devices loaded with FEELM atomizer are now being exported to over 50 countries and regions.”
“FEELM can only realize its corporate vision – “atomization makes life better” – by being sustainable and creating value for society. Every day we move a step closer to this goal by creating sustainable advanced technologies and products, using responsible marketing, and embracing a greener future.”
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom